Recro To Acquire Undisclosed Full-Service CDMO For Around $50M, Q2 Earnings Top Estimates

  • Recro Pharma Inc REPH has signed a non-binding letter of intent to acquire a full-service contract development and manufacturing organization (CDMO) for approximately $49.85 million.
  • The target's capabilities range from formulation development to commercial manufacturing for various dosage forms, including oral liquids, sterile injectables, tablets, topicals, liquid/powder-filled capsules, ophthalmic droppers, liposomes, and nano/microparticles.
  • The purchase price will be paid through $25.5 million cash, 9.3 million Recro shares to be issued in six months, and seller notes of $6.1 million. 
  • Recro also reported Q2 sales of $18 million, +16% Y/Y, beating the consensus of $17.10 million.
  • The Company reported EPS of $0.03, surpassing the consensus of EPS loss of $(0.11) versus a loss of $(0.25) a year ago.
  • Adjusted EBITDA was $5.4 million compared to $4.7 million in Q2 FY20.
  • Recro posted an operating income of $1.8 million versus a loss of $(1.02) million last year.
  • Price Action: REPH shares are down 1.28% at $1.94 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: EarningsM&ANewsPenny StocksGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!